Citius Oncology (CTOR) | Financial Analysis & Statements
Financial Overview
Latest Annual: 2024Income Metrics
Revenue
0
Operating Income
-20.6M
Net Income
-21.1M
EPS (Diluted)
-$0.31
Balance Sheet Metrics
Total Assets
84.4M
Total Liabilities
38.2M
Shareholders Equity
46.1M
Debt to Equity
0.83
Cash Flow Metrics
Operating Cash Flow
-12.8M
Free Cash Flow
-4.9M
Revenue & Profitability Trend
Citius Oncology Income Statement From 2022 to 2024
| Metric | 2024 | 2023 | 2022 |
|---|---|---|---|
| Revenue | 0 | 0 | 0 |
| Cost of Goods Sold | - | - | - |
| Gross Profit | - | - | - |
| Operating Expenses | 20.6M | 12.1M | 4.9M |
| Operating Income | -20.6M | -12.1M | -4.9M |
| Pre-tax Income | -20.6M | -12.1M | -4.9M |
| Income Tax | 576.0K | 576.0K | 576.0K |
| Net Income | -21.1M | -12.7M | -5.4M |
| EPS (Diluted) | -$0.31 | -$0.18 | -$0.08 |
Income Statement Trend
Citius Oncology Balance Sheet From 2022 to 2024
| Metric | 2024 | 2023 | 2022 |
|---|---|---|---|
| Assets | |||
| Current Assets | 11.0M | 7.7M | 2.7M |
| Non-Current Assets | 73.4M | 40.0M | 40.0M |
| Total Assets | 84.4M | 47.7M | 42.7M |
| Liabilities | |||
| Current Liabilities | 32.7M | 21.0M | 5.8M |
| Non-Current Liabilities | 5.5M | 1.2M | 576.0K |
| Total Liabilities | 38.2M | 22.2M | 6.4M |
| Equity | |||
| Total Shareholders Equity | 46.1M | 25.5M | 36.3M |
Balance Sheet Composition
Citius Oncology Cash Flow Statement From 2022 to 2024
| Metric | 2024 | 2023 | 2022 |
|---|---|---|---|
| Operating Activities | |||
| Net Income | -21.1M | -12.7M | -5.4M |
| Operating Cash Flow | -12.8M | -9.0M | -4.8M |
| Investing Activities | |||
| Capital Expenditures | - | - | - |
| Investing Cash Flow | - | - | - |
| Financing Activities | |||
| Dividends Paid | - | - | - |
| Financing Cash Flow | 4.9M | 0 | - |
| Free Cash Flow | -4.9M | 0 | 0 |
Cash Flow Trend
Citius Oncology Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
-14.00
Price to Book
8.55
PEG Ratio
-0.19
Profitability Ratios
Profit Margin
0.00%
Operating Margin
0.00%
Return on Equity
-93.64%
Return on Assets
-22.41%
Financial Health
Current Ratio
0.36
Debt to Equity
10.66
Beta
-0.06
Per Share Data
EPS (TTM)
-$0.38
Book Value per Share
$0.50
Revenue per Share
$0.00
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| ctor | 304.8M | -14.00 | 8.55 | -93.64% | 0.00% | 10.66 |
| Zoetis | 70.6B | 28.45 | 15.19 | 52.09% | 27.12% | 145.63 |
| Haleon Plc - ADR | 45.5B | 23.37 | 5.63 | 8.95% | 12.84% | 63.41 |
| Indivior PLC | 1.9B | 530.50 | -6.57 | -0.57% | -5.30% | -1.29 |
| BioCryst | 1.8B | -21.07 | -4.19 | 18.68% | -10.62% | -1.84 |
| Supernus | 1.8B | 28.91 | 1.77 | 6.32% | 9.27% | 3.13 |
Financial data is updated regularly. All figures are in the company's reporting currency.